A complete explanation of the scoring system for the oncotype DX test and it's benefits for early stage, node negative, hormone positive, Her2 negative breast cancer. The trend towards "individualized oncology" in the past ten years has changed the focus from "one size fits all" to examining the genomic characteristics of the tumor cells. Early stage breast cancers treated prior to this diagnostic test were all given chemotherapy. This test identifies tumors who would not respond to chemotherapy and allows these patients to skip this debilitating treatment and treat their cancer with hormone therapy.